Streptococcus pneumoniae (S. pneumoniae)infections are the leading cause of child mortality globally. Currentvaccines fail to induceaprotective immune response towards a conserved part of the pathogen,resulting in newserotypescausing disease. Therefore, new vaccinestrategies are urgently needed.Described is atwo-pronged approach combiningS. pneumoniaeproteins, pneumolysin (Ply) and pneumococcal surface protein A (PspA),with aprecisely defined synthetic oligosaccharide,wherebythe carrier protein actsas a serotype-independent antigen to provideadditional protection. Proof of concept in mice and swine modelsrevealed thatthe conjugatesinhibited colonization of the nasopharynx, decreased the bacterial load and reduced disease severity in the bacteria challenge model. Immunization of piglets provided the first evidence for the immunogenicity and protective potential of synthetic glycoconjugate vaccine in a large animal model.Acombination of synthetic oligosaccharides with proteins from the target pathogen opens the path to create broadly cross-protective ("universal") pneumococcal vaccines.
- Kaplonek, P.
- Yao, L.
- Reppe, K.
- Voß, F.
- Kohler, T.
- Ebner, F.
- Schäfer, A.
- Blohm, U.
- Priegue, P.
- Bräutigam, M.
- Pereira, C. L.
- Parameswarappa, S. G.
- Emmadi, M.
- Ménová, P.
- Witzenrath, M.
- Hammerschmidt, S.
- Hartmann, S.
- Sander, L. E.
- Seeberger, P. H.
Keywords
- Carbohydrate vaccines
- Carrier protein
- Infectious diseases
- Streptococcus pneumoniae
- Vaccines
